Sugi Predict

Sugi Predict / Compounds / SCHEMBL3022976

SCHEMBL3022976

SCHEMBL3022976

COc1ccccc1C(OC(c1ccccc1)(c1ccccc1)c1ccccc1OC)(c1ccccc1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 3/20 0.46
▸ CA2 P00918 3/20 0.46
▸ CA7 P43166 2/20 0.46
▸ CA9 Q16790 2/20 0.46
▸ CA12 O43570 1/20 0.46
▸ CA4 P22748 1/20 0.46
▸ CA14 Q9ULX7 1/20 0.46
▸ ALDH1A1 P00352 3/20 0.39
▸ TP53 P04637 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ ADRA2B P18089 1/20 0.39
▸ PTGS1 P23219 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ NR3C2 P08235 1/20 0.38
▸ KCNA5 P22460 6/20 0.38
▸ HTT P42858 2/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ GAA P10253 2/20 0.37
▸ MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL136228 0.96 CA1 (0.46) CA1CA2CA7CA9CA12
SCHEMBL7713128 0.88 CA1 (0.46) CA1CA2CA7CA9CA12
SCHEMBL6257499 0.88 CA1 (0.46) CA1CA2CA7CA9CA12
SCHEMBL4660364 0.87 CA1 (0.55) CA1CA2CA7CA9CA12
SCHEMBL16987294 0.87 KIF11 (0.43) CA1CA2CA7CA9CA4
SCHEMBL31430103 0.87 NFE2L2 (0.44) CA1CA2CA7CA9CA12
SCHEMBL136230 0.87 NFE2L2 (0.44) CA1CA2CA7CA9CA12
SCHEMBL2368143 0.86 NR3C2 (0.42) CA1CA2CA7CA9CA12
SCHEMBL30886777 0.85 CA1 (0.43) CA1CA2CA7CA9CA12
SCHEMBL5583968 0.85 CA1 (0.43) CA1CA2CA7CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210189392-A1 S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS ALIGOS THERAPEUTICS, INC. 2021-06-24 — — US claimed
WO-2021119325-A1 S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS ALIGOS THERAPEUTICS, INC. (US) 2021-06-17 — — WO claimed
CN-109705124-A A kind of labeled with radioactive fluorine Larotrectinib compound and preparation method thereof 上海健康医学院 2019-05-03 — — CN claimed
WO-2012131077-A1 SOMATOSTATIN MIMETICS NATIONAL UNIVERSITY OF IRELAND, GALWAY (IE) 2012-10-04 — — WO claimed
WO-2005058246-A2 METHOD FOR PREPARING RADIOLABELED THYMIDINE MOLECULAR TECHNOLOGIES, INC. (US) 2005-06-30 — — WO claimed
US-20050131224-A1 Method for preparing radiolabeled thymidine CTI PET SYSTEMS, INC. 2005-06-16 — — US claimed
US-12227691-B2 Breakable emulsifiers HALLIBURTON ENERGY SERVICES, INC. (US) 2025-02-18 — — US disclosed
WO-2024083861-A1 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF SELABTEC SCIENCES, SLU (ES) 2024-04-25 — — WO disclosed
US-20240018489-A1 BIOCATALYSTS FOR THE PREPARATION OF HYDROXY SUBSTITUTED CARBAMATES INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT 2024-01-18 — — US disclosed
US-11713451-B2 Biocatalysts for the preparation of hydroxy substituted carbamates CODEXIS, INC. (US) 2023-08-01 — — US disclosed
WO-2023118961-A1 ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF INTOCELL, INC. (KR) 2023-06-29 — — WO disclosed
WO-2023107161-A1 BREAKABLE EMULSIFIERS HALLIBURTON ENERGY SERVICES, INC. (US) 2023-06-15 — — WO disclosed
US-20230174841-A1 Breakable Emulsifiers HALLIBURTON ENERGY SERVICES, INC. (US) 2023-06-08 — — US disclosed
US-20050131224-A1 Method for preparing radiolabeled thymidine CTI PET SYSTEMS, INC. 2005-06-16 — — US disclosed
US-6342349-B1 A SOLID SUPPORT SUBSTRATE CONTAINING A CLEAVABLE SIGNAL ELEMENT, A SIGNAL RESPONSIVE MOIETY AND A CLEAVABLE SPACER; ANALYTES BIND THE SIGNAL ELEMENT, ANCHORING THE RESPONSIVE MOIETY TO THE ELEMENT SUBSTRATE-ATTACHING END AFTER CLEAVAGE BURSTEIN TECHNOLOGIES, INC. 2002-01-29 — — US disclosed
US-5792608-A Nuclease stable and binding competent oligomers and methods for their use GILEAD SCIENCES, INC. (US) 1998-08-11 — — US disclosed
EP-0289619-B1 PROCESS FOR SYNTHESIZING OLIGONUCLEOTIDES AND COMPOUNDS FOR FORMING HIGH-MOLECULAR PROTECTIVE GROUP DAICEL CHEM (JP) 1995-08-16 — — EP disclosed
EP-0616612-A4 NUCLEASE STABLE AND BINDING COMPETENT OLIGOMERS AND METHODS FOR THEIR USE. GILEAD SCIENCES INC (US) 1995-01-11 — — EP disclosed
EP-0616612-A1 NUCLEASE STABLE AND BINDING COMPETENT OLIGOMERS AND METHODS FOR THEIR USE GILEAD SCIENCES, INC. (US) 1994-09-28 — — EP disclosed
WO-1993012135-A1 NUCLEASE STABLE AND BINDING COMPETENT OLIGOMERS AND METHODS FOR THEIR USE GILEAD SCIENCES, INC. (US) 1993-06-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131224-A1 Method for preparing radiolabeled thymidine TYMP, TYMS, DUT CA1 4668/4885CA2 4858/4885CA7 3394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.